
Konstantinos Rounis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9827034/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Complications following novel therapies for nonâ€small cell lung cancer. Journal of Internal Medicine, 2022, 291, 732-754.	6.0	6
2	Cancer Cachexia and Antitumor Immunity: Common Mediators and Potential Targets for New Therapies. Life, 2022, 12, 880.	2.4	1
3	Effect of corticosteroids on the outcome of patients with advanced non–small cell lung cancer treated with immune-checkpoint inhibitors. European Journal of Cancer, 2021, 145, 245-254.	2.8	52
4	Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy. Cancers, 2021, 13, 1562.	3.7	10
5	MicroRNAs Regulating Tumor and Immune Cell Interactions in the Prediction of Relapse in Early Stage Breast Cancer. Biomedicines, 2021, 9, 421.	3.2	2
6	Mir-34a as predictor of immunotherapy efficacy in NSCLC patients Journal of Clinical Oncology, 2021, 39, e21191-e21191.	1.6	1
7	High Density of NRF2 Expression in Malignant Cells Is Associated with Increased Risk of CNS Metastasis in Early-Stage NSCLC. Cancers, 2021, 13, 3151.	3.7	2
8	Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study. PLoS ONE, 2021, 16, e0252537.	2.5	20
9	A Prognostic Role for Circulating microRNAs Involved in Macrophage Polarization in Advanced Non-Small Cell Lung Cancer. Cells, 2021, 10, 1988.	4.1	9
10	Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study. Translational Lung Cancer Research, 2021, 10, 3538-3549.	2.8	21
11	Circulating miRNAs as Potential Biomarkers in Prostate Cancer Patients Undergoing Radiotherapy. Cancer Management and Research, 2021, Volume 13, 8257-8271.	1.9	3
12	Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a †Real-Life' Setting. Cancers, 2020, 12, 3707.	3.7	12
13	Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy. Cancers, 2020, 12, 1556.	3.7	27
14	Circulating MicroRNAs Regulating DNA Damage Response and Responsiveness to Cisplatin in the Prognosis of Patients with Non-Small Cell Lung Cancer Treated with First-Line Platinum Chemotherapy. Cancers, 2020, 12, 1282.	3.7	17
15	Cancer cachexia syndrome in the prediction of outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): Results from a single-institution, prospective, observational study Journal of Clinical Oncology, 2020, 38, e21644-e21644.	1.6	0
16	Intergration of common clinical and laboratory parameters for predictive modeling of outcome with immune checkpoint inhibitors (ICIs) in patients (pts) with Nnon-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2020, 38, e21609-e21609.	1.6	2
17	Cancer cachexia, sarcopenia and hand-GRIP strength (HGS) in the prediction of outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): A prospective, observational study Journal of Clinical Oncology, 2019, 37, 9099-9099.	1.6	2
18	A new paradox for pCR in BRCA mutation carriers. Translational Cancer Research, 2019, 8, S99-S102.	1.0	0